Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types
Go back to Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types| ASTRAZENECA PLC (NASDAQ: AZN) | Delayed: 92.77 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $92.77 | 52 Week High | $35.04 | |||
| Open | $92.77 | 52 Week Low | $26.97 | |||
| Day High | $92.77 | P/E | N/A | |||
| Day Low | $92.77 | EPS | $0.00 | |||
| Volume | 2,121,761 | |||||
| Daiichi Sankyo Co Limited Sponsored ADR (AMEX: DSNKY) | Delayed: 16.75 -0.22 (1.3%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $16.97 | 52 Week High | $26.24 | |||
| Open | $16.73 | 52 Week Low | $18.86 | |||
| Day High | $16.77 | P/E | N/A | |||
| Day Low | $16.62 | EPS | $0.00 | |||
| Volume | 94,858 | |||||
| Stratcomm Media, Ltd. (NASDAQ: SMMT) | Delayed: 17.59 +0.42 (2.45%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $17.17 | 52 Week High | $19.75 | |||
| Open | $17.36 | 52 Week Low | $4.26 | |||
| Day High | $17.62 | P/E | N/A | |||
| Day Low | $16.82 | EPS | $0.00 | |||
| Volume | 5,754,954 | |||||



